Valuation dashboard for Monte Rosa Therapeutics, Inc. (GLUE) with P/E N/A, P/B 2.38, EV/EBITDA -7.17 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers.
Analysis Summary
Trailing-twelve-month margins: gross margin 92.9%, operating margin -6.3%, net margin -5.6%.
At the current price of $12.65, GLUE has negative trailing earnings (P/E not meaningful) and an ROE of -43.31%. Market capitalisation stands at $1.1B.
Balance sheet quality for GLUE: current ratio of 6.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 2.38 |
| EV / EBITDA | -7.17 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $31.42 |
| vs Current Price | +148.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 2.38 | -43.3% | |
| DAWN | Day One Biopharmaceuticals, Inc. | $2.2B | 5.05 | -23.4% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% |
Price
| Price | $12.65 |
| Market Cap | $1.1B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -43.31% |
| Return on Invested Capital | -28.19% |
| Return on Assets | -23.15% |
| Gross Margin | 92.94% |
| Operating Margin | -633.04% |
| Net Margin | -560.85% |
Related companies: ARVN · AVBP · DAWN · DNA · GERN · MGTX · REPL
Explore sector: Healthcare · Biotechnology
More sections of GLUE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks